

Giosafat Spitaleri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2497563/publications.pdf>

Version: 2024-02-01

20
papers

384
citations

1040056

9
h-index

794594

19
g-index

20
all docs

20
docs citations

20
times ranked

631
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Value of QFR Measured Immediately After Successful Stent Implantation. JACC: Cardiovascular Interventions, 2019, 12, 2079-2088.	2.9	103
2	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. Circulation: Cardiovascular Interventions, 2018, 11, e006023.	3.9	80
3	Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis. Chronic Respiratory Disease, 2017, 14, 117-126.	2.4	43
4	Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation. American Journal of Cardiology, 2017, 120, 1460-1466.	1.6	20
5	Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Cardiac Failure Review, 2022, 8, e12.	3.0	19
6	Predischarge screening for chronic obstructive pulmonary disease in patients with acute coronary syndrome and smoking history. International Journal of Cardiology, 2016, 222, 806-812.	1.7	17
7	Angio-Based Fractional Flow Reserve, Functional Pattern of Coronary Artery Disease, and Prediction of Percutaneous Coronary Intervention Result: a Proof-of-Concept Study. Cardiovascular Drugs and Therapy, 2022, 36, 645-653.	2.6	17
8	Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018. Scientific Reports, 2021, 11, 732.	3.3	14
9	Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation. Journal of Clinical Medicine, 2021, 10, 4601.	2.4	13
10	A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. PLoS ONE, 2017, 12, e0182124.	2.5	12
11	Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION) Tj ETQq1 1 0.784314 rgBT /Over Cardiology, 2018, 121, 1039-1045.	1.6	10
12	The pharmaceutical management of cardiac allograft vasculopathy after heart transplantation. Expert Opinion on Pharmacotherapy, 2020, 21, 1367-1376.	1.8	7
13	Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention. Circulation Journal, 2017, 81, 82-89.	1.6	7
14	Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. EuroIntervention, 2018, 13, 1939-1945.	3.2	7
15	Methods to assess bioresorbable vascular scaffold devices behaviour after implantation. Journal of Thoracic Disease, 2017, 9, S959-S968.	1.4	4
16	Cause of Death in Heart Failure Based on Etiology: Long-Term Cohort Study of All-Cause and Cardiovascular Mortality. Journal of Clinical Medicine, 2022, 11, 784.	2.4	4
17	Incidence of vasoplegic syndrome after cardiac transplantation in patients treated with sacubitril/valsartan. Clinical Transplantation, 2020, 34, e13994.	1.6	3
18	Translational Medicine in Brain Stem Death and Heart Transplantation. Transplantation, 2020, 104, 2258-2259.	1.0	2

#	ARTICLE	IF	CITATIONS
19	How should I treat a bioresorbable vascular scaffold edge restenosis and intra-scaffold dissection?. EuroIntervention, 2018, 13, 1730-1734.	3.2	1
20	Role of Quantitative Flow Ratio in Predicting Future Cardiac Allograft Vasculopathy in Heart Transplant Recipients. Circulation: Cardiovascular Interventions, 2022, 15, e011656.	3.9	1